Recombinant interleukin-11 protein - Kerun Biopharmaceutical

Drug Profile

Recombinant interleukin-11 protein - Kerun Biopharmaceutical

Latest Information Update: 13 Jun 2016

Price : $50

At a glance

  • Originator Kerun Biopharmaceutical
  • Class Antineoplastics; Chemoprotectants; Interleukins; Recombinant proteins
  • Mechanism of Action Haematopoiesis stimulants; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Registered Thrombocytopenia

Most Recent Events

  • 13 Jun 2016 Registered for Thrombocytopenia in China (unspecified route) before June 2016
  • 31 Dec 1999 Kerun Biopharmaceutical receives approval for conducting clinical trials for recombinant interleukin-11 protein in thrombocytopenia in China (Kerun Biopharmaceutical website) before December 1999
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top